Gevokizumab, a neutralizing humanized monoclonal antibody specific to IL-1β (Figure 2b), given as 60 mg subcutaneously every 4 weeks for 12 weeks, showed its efficacy in a case study of two patients with generalized pustular psoriasis, which resulted in a decrease in generalized pustular psoriasis area and severity index (GPPASI) scores by reductions of 79% and 65% at weeks 4 and 12, respectively [32]. The gene discussed is IL1B; the disease is psoriasis 14, pustular.